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Background: Fluralaner is a novel systemic insecticide and acaricide that provides long acting efficacy in dogs after
a single oral treatment. This study investigated the safety of oral administration of fluralaner in chewable tablets to
dogs at the highest recommended treatment dose and at multiples of this dose.
Methods: Thirty-two (16 male and 16 female) healthy 8-week old Beagle dogs weighing 2.0 - 3.6 kg at first administration
were included in the study. Fluralaner was administered on three occasions at 8-week intervals at doses of up to 56, 168,
and 280 mg fluralaner/kg body weight, equivalent to 1, 3, and 5 times the highest recommended treatment dose of
fluralaner; sham dosed dogs served as controls.
During the study, all dogs were clinically observed, and their health was carefully monitored including body weight
development, food consumption and measurement of hematology, coagulation, clinical chemistry (including
measurement of levels of ACTH and C-reactive protein) and urinalysis. Following euthanasia of the dogs, complete gross
post mortem examination, including organ weight determination, and histopathological examination of multiple tissues
were conducted.
Results: There were no clinical findings related to fluralaner treatment. Statistically significant differences between the
treated groups and the control group were observed for some clinical pathology parameters and organ weights; none of
these findings were considered to be of clinical relevance.
Conclusions: Oral administration of fluralaner at the highest recommended treatment dose (56 mg/kg) at 8-week
intervals is well tolerated and has a safety margin of more than five in healthy dogs eight weeks of age or older and
weighing at least 2 kg.
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Fluralaner is a novel systemically administered insecticidal
and acaricidal product that provides long acting efficacy
after oral administration to dogs. Fluralaner belongs to a
new class of compounds with antiparasitic activity, the iso-
xazolines. These compounds have activity against γ-
aminobutyric acid- (GABA-) and glutamate-gated chloride
channels with significant selectivity for insect neurons
over mammalian neurons [1]. A field study has shown
that a single fluralaner dose administered orally to dogs
provides at least twelve weeks of flea- and tick control [2].* Correspondence: feli.walther@msd.de
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unless otherwise stated.This long duration of activity offers a more convenient
treatment over monthly flea and tick control treatments
with a potential compliance advantage.
This study was designed to demonstrate the safety of
this systemic treatment and to investigate any possible
health impact from repeated oral administration to healthy
dogs of either the highest recommended dose or multiple
overdoses.Methods
This randomized, parallel-group, blinded study included
32 (16 male and 16 female) healthy 8-week old Beagle
dogs. A total of 24 dogs received fluralaner repeatedly
and 8 sham dosed dogs served as controls. The studyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Study dog body weights and ages at the time of
first treatment
Parameter Group




Range 2.1 - 2.8 2.0 - 3.6 2.0 - 3.3 2.0 - 3.0
Mean 2.6 2.8 2.8 2.7
Age (days) Range 56 - 62 54 – 62 56 – 59 54 – 62
Mean 58 57 57 58
Table 2 Fluralaner dose range administered to dogs in
each group
Treatment Dose range per group (mg/kg)
Fluralaner Fluralaner Fluralaner
1X 3X 5X
First treatment (day 0) 31.3 – 56.3 139.4 – 168.8 255.2 – 281.3
Second treatment (day 56) 47.2 – 55.6 153.1 – 163.0 253.1 – 272.5
Third treatment (day 112) 43.1 – 55.3 151.5 – 166.0 254.2 – 277.8
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requirements for veterinary pharmaceutical products [3].
This study was conducted in Ireland in compliance with
the Irish national animal protection legislation framework.
The study plan was approved by the ethics committee of
Charles River Laboratories Preclinical Services Ireland
Ltd. The experimental license number of the investigator
was B100/3771.
Beagle pups were enrolled in the study on day −14
(start of acclimation) and were found to be healthy on
initial physical and clinical pathological evaluation. Dogs
received sulfadiazine and trimethoprim during acclima-
tion for prophylaxis of coccidiosis, which might occur in
dog colonies. Fecal samples collected from all dogs prior
to study start revealed coccidia for several samples; how-
ever, all dogs were in good general health and therefore
included in the study. Dogs were housed in a climate
controlled room (16° - 20°C) with a day length of 10 hours
light and 14 hours darkness and fed a standard commer-
cial diet at recommended rates. Dogs were housed indi-
vidually from day −3 to the end of the study. All dogs
were vaccinated once against Bordetella bronchiseptica
and canine parainfluenza virus and twice (5 weeks apart)
against canine distemper virus, canine adenovirus 2, ca-
nine parvovirus, canine parainfluenza virus and Leptospira
interrogans with the second vaccine given 22 days after
the first fluralaner treatment/sham dosing. All dogs re-
ceived praziquantel, pyrantel embonate, and febantel be-
fore and 22 days after the first fluralaner treatment/sham
dosing for intestinal parasite infection. No clinical findings
were observed in any dog in association with the vaccin-
ation or deworming.
Dogs were randomly allocated into groups using a block
randomization procedure. Dogs were separated by gender
and ranked in descending order of body weight. If two dogs
had the same bodyweights, the dogs were sub-ranked by
decreasing microchip number. The top four dogs within
each gender formed a block that was randomly allocated to
each of the four groups, and the process repeated until 4
male and 4 female dogs were allocated to each group.
Three groups received fluralaner at different doses and one
group served as sham dosed control.
The recommended dose range of fluralaner during rou-
tine clinical use is between 25 and 56 mg/kg [2,4]. This
study evaluated the oral administration of fluralaner, for-
mulated as a chewable tablet, at up to 1, 3, or 5 times the
highest recommended treatment dose, i.e. up to 56 (1X
group), 168 (3X group), or 280 (5X group) mg fluralaner/
kg body weight. The tablet formulation used was the final
commercial formulation intended to be marketed as
Bravecto™ [MSD Animal Health, 4], produced under Good
Manufacturing Practice (GMP). Dogs were administered
fluralaner three times at 8-week (56 days) intervals on days
0, 56 and 112, with the first dose administered at 8 weeks(54–62 days) of age and 2.0 - 3.6 kg of body weight
(Table 1). The dogs were weighed before each fluralaner
treatment to calculate the appropriate dose. A single
whole tablet or a combination of whole tablets, containing
112.5 mg or 250 mg fluralaner, were administered to each
dog to deliver a dose as close as possible to the calculated
dose (Table 2). Following tablet administration, a small
amount of water was administered to encourage swallow-
ing. Dogs from the control group were not administered
fluralaner and were sham dosed with water on days 0, 56
and 112. On treatment days, dogs of all groups received a
portion of their normal daily ration of food approximately
10 to 20 minutes prior to treatment and the remaining
portion of the daily ration directly after treatment. Dogs
were fed around the time of treatment to ensure high sys-
temic fluralaner exposure, since fluralaner bioavailability is
higher in fed dogs [5].
Dogs were observed twice daily for general health
throughout the study. In addition, all dogs were observed
by a technician for signs like gagging, salivation, tablet re-
gurgitation or vomiting during the first hour following each
treatment. Detailed clinical assessments were performed by
a veterinarian, who was blinded (masked) to the treatment
each dog had received, before each treatment and at 1, 2, 3,
4, and 8 hours after each treatment. These examinations in-
cluded assessments of abnormalities in behaviour, coat,
locomotion, respiration, eyes (discharge, mydriasis, miosis,
corneal opacity), mucous membranes, salivation, ausculta-
tion of heart, vomitus, feces and urine as present in pen,
and any other visible abnormalities. Physical examinations
were performed by a blinded veterinarian for all dogs on
days −14, −7, −1, 1, 55, 57, 111, 113 and 167. These
Table 3 Clinical pathology parameters analyzed and
mean results of day 162 for the control group and the
fluralaner 5X group
Parameter (unit) Control fluralaner
5X
Hematology Basophils (x 10^9/L) 0.175 0.171
Eosinophils (x 10^9/L) 0.368 0.748
Hematocrit (L/L) 0.476 0.451
Hemoglobin (g/dL) 15.24 14.29
Large unclassified cells (x 10^9/L) 0.04 0.06
Lymphocytes (x 10^9/L) 3.81 4.13




Mean corpuscular volume (fL) 65.69 67.14
Monocytes (x 10^9/L) 0.56 0.60
Neutrophils (x 10^9/L) 6.67 6.65
Platelets (x 10^9/L) 506 536
Red blood cells (x 10^12/L) 7.24 6.74
Reticulocytes (x 10^9/L) 70.8 53.3




Fibrinogen (mg/dL) 128.3 172.0




chemistry Alanine aminotransferase (U/L) 41.9 39.3
Albumin (g/L) 34.75 33.13
Albumin/globulin ratio 1.96 1.65
Alkaline phosphatase (U/L) 70.50 72.00
Amylase (U/L) 900 800
Aspartate aminotransferase (U/L) 37.63 35.75
Calcium (mmol/L) 2.77 2.76
Chloride (mmol/L) 113.50 115.13
Cholesterol (mmol/L) 5.96 5.68
Creatine kinase (U/L) 306.5 223.4
Creatinine (μmol/L) 54.25 50.50




Globulin (g/L) 18.13 20.38
Glucose (mmol/L) 6.24 6.24
Inorganic phosphate (mmol/L) 2.14 2.14
Lactate dehydrogenase (U/L) 32.50 23.88
Magnesium (mmol/L) 0.69 0.71
Phospholipid (mmol/L) 6.03 5.83
Potassium (mmol/L) 4.75 4.75
Table 3 Clinical pathology parameters analyzed and
mean results of day 162 for the control group and the
fluralaner 5X group (Continued)
Sodium (mmol/L) 148.6 147.8
Total bile acids (μmol/L) 5.98 4.51
Total bilirubin (μmol/L) 1.78 2.10
Total protein (g/L) 52.88 53.38
Triglycerides (mmol/L) 0.44 0.34
Urea (mmol/L) 5.20 4.08
Urinalysis Bilirubin (mg/dL), ketones
(mg/dL), glucose (mg/dL), turbidity
0 0
Blood pigments (mg/dL) 0.029 0.004
Leukocytes (cells/μL) 150 106
pH 6.44 6.44
Protein (mg/dL) 8.75 5.00
Specific gravity 1.031 1.025
Urobilinogen (mg/dL) 0.40 0.20
Volume (mL) 133 153
Urine color Light yellow - yellow
Microscopic examination
(crystals, casts, red blood cells,
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haviour, locomotion, musculoskeletal system, coat, skin,
superficial lymph nodes, eyes, pupils, ears, oral cavity, mu-
cous membranes, capillary refill time, respiration, ausculta-
tion of heart and respiratory tract, heart rate, respiratory
rate, pulse, abdominal palpation, rectal temperature, any
other visible abnormalities and body condition scaled 1
(cachexia) to 5 (adiposity).
The individual food consumption was recorded daily
and body weights were recorded weekly throughout the
study. Blood samples were collected for clinical pathology
(hematology, coagulation, clinical chemistry including
ACTH and C-reactive protein; Table 3) before the first
treatment and on days 8, 50, 106 and 162; and to monitor
systemic exposure to fluralaner before and 2, 7, 14 and
28 days after each treatment. Urine samples were taken
before the first treatment and on days 7/8, 49/50, 105/106
and 161/162.
To complete the safety assessment, all dogs underwent a
post mortem examination, as required by VICH GL 43 [3].
On day 168, all dogs were sedated by intramuscular injec-
tion of ketamine and xylazine and thereafter euthanized by
intravenous injection of sodium pentobarbitone as per
study plan. A complete post-mortem examination was per-
formed on all dogs under the supervision of a blinded vet-
erinary pathologist. Selected organs were weighed and
multiple tissues were examined histopathologically (Table 4).
Tissue samples were formalin-fixed (epididymides and eyes
Table 4 Table of organs and tissues examined


















Uterus with cervix √
Trachea, lung -
Eyes, sciatic nerve -
Different sections of spinal cord -






Different section of gastro-intestinal tract, Peyer’s
patches
-
Femur, stifle joint with bone, sternum -
Skeletal muscle -
Skin, mammary gland -
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Davidson’s fixative) and paraffin-embedded. Microscopy
slides were stained with hematoxylin and eosin stain. Add-
itional formalin-fixed frozen oil red O stained slides were
prepared for heart, kidney and liver to ascertain the pres-
ence of fat. Femur bone marrow smears were prepared and
stained with May Grunewald’s Giemsa stain. All samples
were assessed by a veterinary histopathologist.
Body weight, food consumption (averaged over weekly
intervals), physical examination results, clinical pathology
parameters and absolute and relative organ weights were
statistically compared between groups (SAS® Language:Reference, Version 9.3, SAS Institute Inc., Cary, NC, USA)
using 2 sided tests with the individual dogs as the experi-
mental unit to evaluate the hypothesis that there are
no differences between the groups. Body weight, food
consumption, clinical pathology parameters (including
numeric urinalysis parameters), heart rate and rectal
temperature were analyzed using a repeated measured
mixed model analysis of covariance. Categorical urinaly-
sis parameters were analyzed using descriptive statistics.
Organ weights were analyzed using analysis of variance
models. Frequency distributions of the numbers of ani-
mals with abnormalities during clinical assessments or
physical examinations were compiled for categorical
parameters.
For clinical pathology parameters study-specific reference
ranges were compiled, as these values were considered
most suitable for the dog population examined. These ref-
erence ranges included results from the control group at all
collection time points (before the first sham dosing and
on days 8, 50, 106 and 162) and from the fluralaner-treated
groups before the first treatment. In support, reference
ranges from historical controls, the clinical pathology
laboratory or from literature may be used to assess results
[6]. All clinical pathology parameters found to be statisti-
cally significantly different were compared with these
study-specific reference ranges to evaluate the clinical rele-
vance. Individual values outside these reference ranges
were assessed for possible clinical relevance. Clinical rele-
vance was assessed by the veterinary investigator based on
the following criteria: transience (temporary observation),
dose–response relationship, values close to or within the
reference ranges, association with evidence of clinical signs
and with tissue changes on gross post mortem or histo-
pathological examination.
The veterinary investigator assessed all parameters re-
corded and any findings for their relationship to flurala-
ner treatment. Any clinically relevant treatment-related
findings were classified as adverse events.
Results and discussion
There were no findings related to the treatment with
fluralaner for any of the parameters assessed.
The 8-week treatment interval used in the present study
is expected to be shorter than the recommended 12-week
treatment interval for fluralaner tablets in clinical veterin-
ary practice [2,4]. An 8-week treatment interval was se-
lected in this study to provide data for clinicians who may
select a shorter treatment interval under field conditions
[4], and to provide an additional safety margin compared
with the expected field use conditions.
The highest fluralaner dose administered during the
study was in an eight-week old dog in the 5X group (281.3
mg/kg; Table 2). Fluralaner was administered on three
occasions as previous pharmacokinetic data (unpublished
Table 5 Clinical findings in dogs of treated and control groups following the first treatment
Observation Number of dogs affected Analysis Conclusion
Scattered incidences of abnormal feces
(loose, mucoid, traces of fresh blood)
Total observed: n = 15 Similar number of animals affected in each treated
group compared to controls; abnormal feces
already observed pre-treatment across all groups
Not treatment related,
no adverse event
Control group: n = 4
1X group: n = 5
3X group: n = 3
5X group: n = 3
Reduced body condition score
(2 or 2–3 on a scale of 1–5)
Total observed: n = 8 Similar (3X group, 5X group) or lower (1X group)




Control group: n = 3
1X group: n = 0
3X group: n = 3
5X group: n = 2
Localized hair thinning/pressure
wound/wound
Total observed: n = 6 Similar (1X group, 5X group) or lower (3X group)




Control group: n = 2
1X group: n = 3
3X group: n = 0
5X group: n = 1
Vomiting of food after first treatment,
no other clinical findings
Total observed: n = 1 Single case; no dose–response relationship;
not observed following repeated treatment
Not treatment related,
no adverse event
Control group: n = 0
1X group: n = 1
3X group: n = 0
5X group: n = 0
Gastroenteritis with inappetence,
dullness, vomit
Total observed: n = 1 Single case; no dose–response relationship;
not observed following repeated treatment
Not treatment related,
no adverse event
Control group: n = 0
1X group: n = 0
3X group: n = 1
5X group: n = 0
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cient to achieve steady state plasma concentrations. Admin-
istration of three sequential treatments at 8-week intervals
produced a 24-week study period with the highest systemic
exposure to fluralaner at doses of five times the highest rec-
ommended treatment dose. To further ensure peak plasma
concentrations in treated dogs, fluralaner was adminis-
tered at the time of feeding, since fluralaner bioavailability
is higher in fed dogs [5]. All dogs partially or totally con-
sumed the diet offered prior to the first treatment (day 0)Table 6 Frequency distribution by group of dogs with abnorm
Time point No. of animals with abnormalities
recorded per group
Control group 1X group 3X group 5X group
Clinical assessment 2 5 1 1
Physical examination 4 4 4 3and totally consumed the diet offered prior to the second
and third treatment (day 56 and 112).
Fluralaner was quantifiable in the plasma of all treated
dogs, confirming absorption and systemic exposure.
Throughout the 24-week study, no differences in growth
rates or food consumption between the treated groups
and the control group were observed.
All dogs were carefully observed for any clinical findings
during the first hours following treatment to cover the
period of rapidly increasing systemic fluralaner exposurealities recorded following the first treatment
Analysis Conclusion
Number of animals with abnormalities higher
in 1X group than in controls, but similar to controls in
3X and 5X group; no dose–response relationship
Not treatment
related
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ent. However, no clinical findings related to the treatment
with fluralaner were observed throughout these frequent
observations following any of the fluralaner treatments
on days 0, 56 and 112, or throughout the remainder of the
study. Two cases of vomiting occurred during the study.
One dog treated with a 1X dose for the first time vomited
4 hours after treatment. This dog was not administered a
second dose based on the canine gastric emptying half-
time of approximately 3 hours in fed dogs [8]. Absorption
of the administered dose was confirmed by dose-related
plasma concentrations of fluralaner. This dog remained in
the study and did not show any other clinical signs (in-
cluding vomiting) in the remainder of the study. Another
dog developed signs of gastroenteritis (vomiting and diar-
rhea) 5 days after administration of the first fluralaner
dose at 3 times the highest recommended treatment dose.
The dog was treated with injectable antibiotics (enro-
floxacin) and clinical signs resolved fully over the next
four days. These clinical signs were considered to be
unrelated to fluralaner administration due to the 5-day
interval between fluralaner treatment and the onset of
clinical signs, as well as the subsequent rapid resolution
of clinical signs following antibacterial treatment. This
dog did not show any further signs of gastroenteritis
and remained in the study.
Occasional clinical findings were observed in individual
dogs from the treated and control groups, during the 168-
day study (Table 5). Clinical findings included incidences
of mild abnormal feces (small amount of loose feces, small
amount of mucoid feces/mucus in feces, traces of fresh
blood), slight reductions in body condition score (2 or 2–3
on a scale of 1–5), or mild superficial skin injury; all of
these were minor and none affected the general health
condition of dogs. These observations were considered to
be unrelated to fluralaner treatment because they occurred
at a similar or lower incidence in the treated groups
compared with the control group and without a dose–
response relationship. In addition, abnormal feces were
observed before the first treatment across all groups. Al-
though all dogs were treated with endoparasiticides, intes-
tinal parasite infections, like coccidia or giardia, may have
been supportive in the occurrence of incidences of mild
abnormal feces observed pre- and post-treatment. Based
on the frequency distribution of the number of dogs with
abnormal findings during clinical assessments or physical
examinations, there were no dose-related differences be-
tween groups (Table 6). Treated dogs were found to have
statistically significant lower mean rectal temperatures than
control dogs at six time points (days 55 and 167 – 1X
group; days 55, 111 and 167 – 3X group; and day 55 – 5X
group). This difference was not considered to be of clinical
relevance because there were no clinical signs or significant
changes in clinical pathology in the treated dogs, and therectal temperatures of all treated dogs were within the
range observed in control dogs.
Statistically significant differences between the treated
groups and the control group were observed for some
clinical pathology parameters and organ weights and a
few individual single time point clinical pathology results
fell outside the reference ranges. All of these findings
were evaluated based on the assessment criteria and
were not considered to be clinically relevant. Gross post
mortem and histopathological examinations found no
notable differences between the treated groups and the
control group (data not shown).
The evaluation of the present study is consistent with
the conclusion drawn by authorities [4].
Conclusions
This detailed evaluation of the safety of fluralaner, a novel
systemic antiparasitic drug, following oral administration at
doses much higher than the recommended treatment dose
at 8-week intervals, did not reveal any adverse events.
Oral administration of fluralaner, formulated as a chewable
tablet, to healthy dogs at dose rates of up to 281.3 mg/kg
on three occasions at 8-week intervals did not lead to any
treatment-related findings that could be detected through
careful clinical observation, clinical pathological evaluation
or on gross or microscopic post mortem examination. Oral
administration of fluralaner at the highest recommended
treatment dose (56 mg/kg) is well tolerated by dogs and
has a safety margin of more than five in healthy dogs eight
weeks of age or older and weighing at least 2 kg.
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